Participated · Equity · Mar 2020

Enovix develops advanced lithium-ion batteries that incorporate a 100% active silicon anode using a patented 3D cell architecture to increase energy density while maintaining high cycle life. The company has also developed proprietary roll-to-stack production tools that 'drop in' to existing lithium-ion manufacturing lines and can raise MWh capacity by about 30%. Enovix completed construction and is installing equipment at its first production facility to begin commercial delivery in 2021. To date the company has raised over $225 million in venture, strategic and private funding. Enovix has been awarded more than 90 patents and has over 50 additional applications pending to build sustainable enterprise value and competitive barriers. Eclipse Ventures recently made a significant investment and its partner Greg Reichow joined Enovix's board to counsel on scaling production operations. Enovix has developed a lithium‑ion battery that uses a 100% active silicon anode within a patented 3D cell architecture to raise energy density while maintaining high cycle life. The company also designs production tools that can 'drop in' to existing roll‑to‑roll battery lines and claim to raise MWh capacity by about 30%. Funds from its 2020 raise are earmarked to build, equip and staff its first U.S. production facility in Fremont, California, aimed at mass‑market applications. Enovix is working under contract with several category‑leading customers and recently signed a commercial supply agreement, with plans to begin commercial delivery of its 3D silicon lithium‑ion battery in 2021. The company highlights strategic relationships with Intel and Qualcomm and reports 81 awarded patents with 49 applications pending. As of the announced raise, total funding stands at over $220 million. Enovix has developed a lithium‑ion battery that uses a 100% active silicon anode and a patented 3D cell architecture to boost energy density while maintaining high cycle life. The company intends to complete its Fremont, California facility to produce and commercialize its 3D silicon lithium‑ion batteries, with initial deliveries expected in late 2020 and a planned run‑rate of 8 million units per year as it ramps in 2021–2022. Enovix has agreements with four category‑leading customers to develop and produce silicon‑anode batteries for portable electronic devices, representing an anticipated $250 million in annual revenue once fully ramped. It is also working with leading international automobile manufacturers to adapt its technology for the electric vehicle market. The company is backed by strategic relationships with Intel, Qualcomm and Cypress and has previously raised over $200 million in venture, strategic and private funding. Recent financing includes $45 million secured from a mix of a major new strategic investor, current investors and non‑dilutive customer funding.

Participated · Series E · Dec 2017

Insightec develops and commercializes the Exablate Prime focused-ultrasound platform to provide incisionless, immediate tremor treatment for patients with medication-refractory essential tremor and Parkinson’s disease. The Exablate Prime platform is FDA approved for those indications. The company reports over 160 systems installed worldwide and its technology has been used in nearly 20,000 commercial applications. Led by CEO Maurice R Ferré, Insightec is based in Haifa, Israel and Miami, FL, and also has offices in Dallas, Shanghai, and Tokyo. The company raised $150M in equity financing and intends to use the funds to expand operations and advance its development efforts. Insightec develops and commercializes the Exablate Neuro platform, which uses MRI‑guided acoustic energy to deliver incisionless neurosurgery for medication‑refractory Essential Tremor and Parkinson’s Disease. The company is led by CEO Maurice R. Ferré and is conducting research and clinical trials to expand applications into neuro‑oncology and other neurological conditions in partnership with academic and medical institutions. Insightec intends to drive broader adoption of its incisionless treatments while continuing to advance innovation and clinical research. Financially, the company signed a credit facility for up to $200 million with affiliates of existing shareholders Perceptive Advisors and Community Fund, receiving $100 million at closing. The facility is interest‑only for five years and matures on August 31, 2027, with an additional $100 million potentially available in tranches through 2024. The company operates from Haifa, Israel and Miami, Florida, and has additional offices in Dallas, Shanghai, and Tokyo. Insightec makes a magnetic resonance–guided focused ultrasound device that ablates the thalamus using high‑intensity sound waves to reduce hand tremors without an incision. The device is approved by the FDA to treat essential tremor in patients unresponsive to medication and has expanded approval for tremor‑dominant Parkinson’s disease. The procedure is unilateral and currently can be performed on only one side of the brain, typically addressing the dominant hand. The company has redirected focus toward neurology after earlier work on other indications, such as uterine fibroids, saw limited hospital traction. Insightec has sold its technology to more than 65 health systems worldwide, and a study of 76 essential tremor patients funded in part by the company reported 58% of patients had at least a 50% improvement in hand tremor and function at three years. Its global headquarters is in Israel and its U.S. headquarters is in Miami. Insightec is a commercial-stage medical device company that develops MRI-guided focused ultrasound platforms for non-invasive surgical therapies. Its therapy platforms, Exablate and Exablate Neuro, are proven technologies with clinical evidence for treating essential tremor, painful bone metastases and uterine fibroids. Led by Maurice R. Ferré, MD, CEO and Chairman of the Board, the company brings solutions to patients by collaborating with physicians, medical institutions, academic researchers and regulatory bodies worldwide. Insightec is based in Haifa, Israel, and Miami, Florida, and also maintains offices in Dallas, Tokyo and Shanghai. The company intends to use new funds to further commercialize its approved indications and to continue research into Parkinson’s disease, Alzheimer’s disease and brain tumors. It recently raised $150M in a Series E pre-IPO financing. Insightec develops a non-invasive therapy platform based on Magnetic Resonance-guided Focused Ultrasound (MRgFUS). Founded in 1999 and based in Dallas, Texas and Haifa, Israel, the company’s technology is already used by physicians in more than 120 medical facilities worldwide. Its indications are expanding across neurosurgery, oncology and gynecology. The company is privately held by GE Healthcare, Elbit Imaging, York Capital Management, GEOC Hengtong Investment Limited Partnership and MediTech Advisors. Insightec recently secured $22M in a Series D financing. Leadership will transition to newly appointed CEO Dr. Maurice R. Ferré, while founder and former CEO Dr. Kobi Vortman will move to the board and continue to drive strategy and the product roadmap.